> For the complete documentation index, see [llms.txt](https://www.brexatlas.org/llms.txt). Markdown versions of documentation pages are available by appending `.md` to page URLs; this page is available as [Markdown](https://www.brexatlas.org/bre-001/bre-036.md). # BRE 036 ## TTFields Clinical Translation and Systems-Level Therapy in Glioblastoma **Clinical Cancer Name:** Glioblastoma\ **Common Cancer Name:** Aggressive Brain Cancer ## Source Rominiyi, O., Vanderlinden, A., Clenton, S. J., Bridgewater, C., Al-Tamimi, Y., & Collis, S. J. (2020).\ *Tumour treating fields therapy for glioblastoma: current advances and future directions.*\ *British Journal of Cancer, 124, 697–709.* *** ## BRS Score **BRS:** 9.4 / 10\ **STEMD:** S10 / T10 / E9 / M9 / D9\ **External Evidence Level:** High clinical + translational review evidence ## Score Interpretation BRE-036 receives one of the strongest scores because it integrates clinical trial evidence, glioblastoma treatment optimization, and mechanistic synthesis. Its value is strongest as a clinical translation bridge between laboratory TTFields mechanisms and real-world glioblastoma therapy systems. *** ## Entry Summary BRE-036 asks a clinically important question: How do Tumor Treating Fields move from laboratory mechanism into real glioblastoma treatment systems? This review explains TTFields as more than one isolated mechanism. It organizes TTFields as a broad anticancer modality affecting: * mitosis * DNA repair * autophagy * membrane permeability * migration * immune signaling * therapeutic sensitization In simple language: TTFields are not just “electric fields that stop cells from dividing.” They appear to affect several cancer survival systems at the same time. *** ## What BREXAtlas Found BREXAtlas identifies this primary mechanism chain: TTFields\ ↓\ Tubulin alignment disruption\ ↓\ Mitotic spindle destabilization\ ↓\ Septin disruption\ ↓\ Cytokinetic failure\ ↓\ Mitotic catastrophe\ ↓\ Tumor-cell death A DNA vulnerability chain is: TTFields\ ↓\ BRCA / Fanconi suppression\ ↓\ Replication stress\ ↓\ Persistent DNA damage\ ↓\ Impaired homologous recombination\ ↓\ Therapeutic sensitization An immune activation chain is: TTFields\ ↓\ Immunogenic cell death\ ↓\ ATP / HMGB1 release\ ↓\ Dendritic-cell activation\ ↓\ CD8+ T-cell recruitment\ ↓\ Antitumor immune activation A membrane chain is: TTFields\ ↓\ Increased membrane permeability\ ↓\ Enhanced chemotherapy penetration\ ↓\ Amplified therapeutic response Together, these chains make BRE-036 a central applied TTFields entry. *** ## Questions This BRE Helps Answer
What is glioblastoma? Glioblastoma is an aggressive brain cancer. It is difficult to treat because it grows quickly, invades brain tissue, and often returns after treatment. **What BREXAtlas found:**\ BRE-036 places TTFields inside glioblastoma clinical translation, including 200 kHz optimization, long daily treatment compliance, array planning, and combination with temozolomide.
What frequency is clinically important for glioblastoma? **What BREXAtlas found:**\ Clinical glioblastoma TTFields optimization centers around 200 kHz, with a broader TTFields range of 100–300 kHz and 1–3 V/cm. This makes BRE-036 a key frequency reference entry.
Why does treatment time matter? TTFields therapy depends heavily on duration of use. **What BREXAtlas found:**\ The extraction identifies greater than 18 hours per day as an important exposure/compliance optimization variable. For patients and families, this means the device is not just a medicine dose. It is also a daily-use system.
Does TTFields only disrupt mitosis? **What BREXAtlas found:**\ No. BRE-036 supports TTFields as a multi-mechanism therapy affecting mitosis, DNA repair, autophagy, permeability, migration, immune signaling, and treatment sensitization.
*** ## Study Classification | Category | Classification | | --------------------------------------- | ------------------------------------------------------- | | Study Type | Clinical review / translational TTFields systems review | | Tissue Category | Glioblastoma; glioma; central nervous system oncology | | Models | U-87 MG, U-118 MG, F98, multiple glioblastoma systems | | Frequency Range | 100–300 kHz | | Clinical GBM Frequency | 200 kHz | | Field Strength | 1–3 V/cm | | Exposure Optimization | >18 h/day | | Direct TTFields Evidence | Yes, review-supported | | Clinical Translation Evidence | Yes | | Suitable for Glioblastoma Index | Yes | | Suitable for Clinical Translation Index | Yes | | Suitable for Frequency Index | Yes | | Suitable for Systems Mechanism Index | Yes | *** ## Mechanisms ### MEC-001: Mitotic Disruption TTFields disrupt mitotic spindle formation and cell division. ### MEC-003: DNA Repair Interference TTFields may suppress BRCA/Fanconi pathways and impair homologous recombination. ### MEC-004: Immunogenic Cell Death TTFields may trigger immunogenic signaling through ATP and HMGB1 release. ### MEC-009: Immune Modulation TTFields may support dendritic-cell activation and CD8+ T-cell recruitment. ### MEC-015: DNA Damage Persistence DNA damage may persist when repair pathways are weakened. ### MEC-016: Septin Mislocalization TTFields may disrupt septin organization during division. ### MEC-022: Cytokinetic Furrow Destabilization TTFields may interfere with the final stage of cell division. ### MEC-047: Blood-Brain Barrier Permeability Modulation TTFields may alter membrane and barrier permeability properties, potentially enhancing therapeutic penetration into glioblastoma systems. ### MEC-048: TTFields-Induced Immune Recruitment TTFields-induced immunogenic signaling may enhance immune-cell recruitment and adaptive immune activation. *** ## Discoveries ### DISC-005: Combination Therapy Amplification BRE-036 supports TTFields as a treatment amplifier when combined with therapies such as temozolomide. ### DISC-006: Mitotic Structural Collapse Network BRE-036 reinforces the structural-collapse pathway from BRE-014 through BRE-016. ### DISC-007: Replication Stress and DNA Vulnerability BRE-036 supports DNA repair suppression and replication stress as recurring TTFields pathways. ### DISC-021: Clinical Systems-Level TTFields Integration BREXAtlas identifies this as a major discovery: Clinical and mechanistic evidence suggests TTFields function as a systems-level therapeutic platform integrating mitotic, immune, DNA-repair, membrane-signaling, and treatment-amplification vulnerabilities. *** ## Connections to Other BRE Entries ### Connected to BRE-014, BRE-015, and BRE-016 BRE-014 showed mitotic spindle disruption. BRE-015 showed septin disruption. BRE-016 showed cytokinetic furrow vulnerability. BRE-036 integrates these into clinical glioblastoma translation. ### Connected to BRE-018 BRE-018 showed DNA repair suppression and radiation sensitization through BRCA1-related vulnerability. BRE-036 extends DNA repair vulnerability into glioblastoma translational systems. ### Connected to BRE-019 and BRE-020 BRE-019 and BRE-020 synthesized multi-mechanism TTFields pathways. BRE-036 applies that synthesis to clinical glioblastoma systems. ### Connected to BRE-021 BRE-021 emphasized frequency optimization and field delivery. BRE-036 provides glioblastoma-specific clinical optimization: 200 kHz, 1–3 V/cm, and >18 h/day. ### Connected to BRE-005 BRE-005 introduced TTFields immune activation. BRE-036 strengthens that pathway with immunogenic cell death, dendritic-cell activation, and CD8+ T-cell recruitment. *** ## Research Gaps Identified ### RG-177: Clinical Frequency Optimization Gap More work is needed to personalize frequency beyond the standard glioblastoma 200 kHz setting. ### RG-178: TTFields Resistance Mechanism Gap Future research should identify why some tumors respond better than others. ### RG-179: Blood-Brain Barrier Permeability Quantification Gap More measurement is needed to determine how TTFields affects permeability and drug penetration. ### RG-180: Immune-System Biomarker Mapping Gap More studies are needed to identify immune biomarkers that predict TTFields response. ### RG-181: Long-Term Systems Adaptation Gap Future work should determine how glioblastoma adapts under long-term TTFields exposure. ### RG-182: Personalized Field Optimization Gap More research is needed to customize field delivery by tumor location, anatomy, and individual response. *** ## Scientific Caution BRE-036 is a comprehensive review integrating preclinical and clinical TTFields evidence. Mechanistic interpretations remain dependent on the underlying referenced studies and should not be interpreted as independent experimental confirmation. *** ## Why This Entry Matters For researchers, BRE-036 shows how TTFields becomes a clinical systems platform rather than only a laboratory mechanism. For patients and families, the simple idea is this: TTFields are already part of glioblastoma treatment discussions, especially with temozolomide. This review explains why the therapy may work through several cancer weaknesses at once. The major practical issue is that treatment depends heavily on device use, field planning, and continued optimization. *** ## Entry Conclusion BRE-036 is a cornerstone clinical translation entry. Earlier BRE entries explained TTFields mechanisms. BRE-036 shows how those mechanisms connect to glioblastoma treatment systems, patient compliance, field optimization, immune activation, DNA repair vulnerability, membrane permeability, and combination therapy. The central question emerging from this entry is: Can TTFields be optimized as a personalized, multi-mechanism treatment platform for glioblastoma? For BREXAtlas, BRE-036 is essential because it bridges laboratory discovery with real-world clinical application. --- # Agent Instructions This documentation is published with GitBook. GitBook is the documentation platform designed so that both humans and AI agents can read, navigate, and reason over technical content effectively. Learn more at gitbook.com. ## Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter, and the optional `goal` query parameter: ``` GET https://www.brexatlas.org/bre-001/bre-036.md?ask=&goal= ``` `ask` is the immediate question: it should be specific, self-contained, and written in natural language. `goal` is optional and describes the broader end goal you are ultimately trying to accomplish on behalf of the user. GitBook uses it to tailor the answer towards what is most useful for that goal. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.